Stifel Financial Corp boosted its stake in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 2.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,527 shares of the medical instruments supplier’s stock after purchasing an additional 290 shares during the quarter. Stifel Financial Corp’s holdings in Insulet were worth $2,450,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in PODD. QRG Capital Management Inc. bought a new stake in shares of Insulet during the third quarter valued at approximately $297,000. Fisher Asset Management LLC raised its stake in Insulet by 0.9% during the 3rd quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock valued at $81,719,000 after acquiring an additional 3,113 shares in the last quarter. Point72 DIFC Ltd acquired a new position in Insulet during the 2nd quarter worth $554,000. GSA Capital Partners LLP bought a new position in shares of Insulet in the third quarter worth $1,017,000. Finally, LMR Partners LLP acquired a new position in shares of Insulet during the third quarter valued at $3,517,000.
Analysts Set New Price Targets
A number of analysts have commented on PODD shares. Morgan Stanley boosted their price target on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Citigroup upped their target price on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. BTIG Research lifted their price target on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. JPMorgan Chase & Co. boosted their price objective on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research note on Thursday, December 12th. Finally, Raymond James raised their target price on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $267.44.
Insiders Place Their Bets
In other Insulet news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.47% of the company’s stock.
Insulet Trading Down 2.6 %
NASDAQ PODD opened at $256.44 on Thursday. The company has a market capitalization of $17.99 billion, a PE ratio of 43.91, a price-to-earnings-growth ratio of 4.12 and a beta of 1.21. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $279.77. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The firm’s fifty day simple moving average is $253.30 and its 200-day simple moving average is $222.13.
Insulet Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
Further Reading
- Five stocks we like better than Insulet
- Investing in Commodities: What Are They? How to Invest in Them
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- What is Short Interest? How to Use It
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.